RESMED INC

ResMed (RMD) approaches its dividend ex‑date on Aug. 19, amid a stable yet cautious market backdrop. The company’s focus on connected respiratory tech, AI diagnostics, and R&D positions it to capture growth in telehealth while navigating regulatory …

ResMed’s strong earnings and disciplined pricing strategy face a technical pullback; investors weigh solid fundamentals against short‑term volatility in the ASX 200 healthcare sector.

ResMed Inc’s Q4 earnings miss hits stock prices – see how margin cuts, U.S. reimbursement pressures, and digital‑health opportunities could reshape its future.

ResMed’s fiscal 2027 outlook drops $75 M from its Astral ventilator recall, citing supply‑chain strain and freight cost hikes that squeeze margins and shake investor confidence.

ResMed’s FY‑2026 results: $3.18B revenue, 22% margin, and a 10% dividend hike—boosting sleep‑therapy growth and digital health while navigating recalls and new competition.

ResMed’s Class I recall of Astral 100 and 150 ventilators—due to leaking super‑capacitors—details repairs, safety steps, and impact on care.

ResMed Inc. defends steady earnings and cash flow amid market volatility, while its AI‑driven sleep‑health tech positions it for growth in value‑based care.

ResMed (RMD) soars on low‑rate Aussie markets, strong sleep‑apnea pipeline and global diversification – a compelling growth play for long‑term investors.

Katana Capital’s July 2026 update highlights resilient NTA, a strategic tech‑health focus, and ResMed’s inclusion, underscoring its risk‑managed growth strategy.

Australian Foundation Investment Company (AFI) boosts NTA, $9.8B portfolio, top holdings BHP, CBA, Macquarie—low 0.16% fee and long‑term equity focus.